Which concentration of the inhibitor should be used to predict in vivo drug interactions from in vitro data?
Journal Title: The AAPS Journal - Year 2002, Vol 4, Issue 4
Abstract
Authors and Affiliations
Kiyomi Ito, Koji Chiba, Masato Horikawa, Michi Ishigami, Naomi Mizuno, Jun Aoki, Yasumasa Gotoh, Takafumi Iwatsubo, Shin-ichi Kanamitsu, Motohiro Kato, Iichiro Kawahara, Kayoko Niinuma, Akiko Nishino, Norihito Sato, Yuko Tsukamoto, Kaoru Ueda, Tomoo Itoh, Yuichi Sugiyama
Keywords
Related Articles
- EP ID EP682019
- DOI 10.1208/ps040425
- Views 107
- Downloads 0
Pre-Existing Biotherapeutic-Reactive Antibodies: Survey Results Within the American Association of Pharmaceutical Scientists
The immunogenicity profile of a biotherapeutic is determined by a multitude of product and patient-related risk factors that can influence the observed incidence and clinical consequences of immunogenicity. Pre-existing...
Harnessing Biomaterials to Engineer the Lymph Node Microenvironment for Immunity or Tolerance
Nanoparticles, microparticles, and other biomaterials are advantageous in vaccination because these materials provide opportunities to modulate specific characteristics of immune responses. This idea of “tuning&#...
2-Arachidonoylglycerol (2-AG) membrane transport: History and outlook
Only a few studies have addressed the transport of 2-arachidonoylglycerol (2-AG), a naturally occurring agonist for cannabinoid receptors. Based upon saturation kinetics, these early reports have proposed that 2-AG enter...
Virtual coupling of pyran protons in the 1H NMR spectra of C- and N-glucoronides: Dependence on substitution and solvent
We have observed that certain C-and N-glucuronides prepared as intermediates for breast cancer preventives demonstrate non-first order 1H NMR spectra that are not the result of impurities or degradation but are instead d...
Pharmacologic and pharmacokinetic profile of repifermin (KGF-2) in monkeys and comparative pharmacokinetics in humans
Repifermin (truncated, recombinant human keratinocyte growth factor-2, KGF-2) was evaluated in cynomolgus monkeys and healthy humans during a phase 1 trial. Monkeys received vehicle or repifermin at 20, 75, or 200 ...